Patients and treatment
| Characteristics . | −G-CSF, no. (%) . | +G-CSF, no. (%) . |
|---|---|---|
| Total | 461 (100) | 456 (100) |
| Sex male | 239 (52) | 237 (52) |
| Age, y | ||
| ≤ 35 | 83 (18) | 82 (18) |
| 36-50 | 172 (37) | 167 (37) |
| > 50 | 206 (45) | 207 (45) |
| Range | 18-60 | 17-60 |
| Median | 49 | 49 |
| Prior MDS or chemo/RT | ||
| MDS | 18 (4) | 16 (4) |
| Chemo/RT | 27 (6) | 22 (5) |
| WHO performance status | ||
| 0 | 210 (46) | 208 (46) |
| 1 | 216 (47) | 214 (47) |
| 2 | 28 (6) | 27 (6) |
| 3 | 3 (1) | 1 (0) |
| 4 | 1 (0) | 0 (0) |
| Unknown | 2 (0) | 6 (1) |
| Extramedullary disease* | 56 (12) | 81 (18) |
| WBC | ||
| ≤ 20 × 109/L | 282 (61) | 268 (59) |
| 20-100 × 109/L | 126 (27) | 136 (30) |
| > 100 × 109/L | 53 (11) | 52 (11) |
| AML vs RAEB | ||
| AML | 445 (97) | 428 (94) |
| RAEB | 16 (3) | 28 (6) |
| Cytogenetics | ||
| t(8;21) | 20 (4) | 22 (5) |
| inv(16) | 24 (5) | 28 (6) |
| CN-X-Y | 194 (42) | 213 (47) |
| CA Rest | 145 (31) | 109 (24) |
| MK | 58 (13) | 58 (13) |
| Not done | 20 (4) | 26 (6) |
| Treatment | ||
| Induction treatment | ||
| No | 0 (0) | 1 (0) |
| 1 | 56 (12) | 69 (15) |
| 1 + 2 | 405 (88) | 386 (85) |
| Ara-C dose | ||
| Conventional | 359 (78) | 350 (77) |
| Escalated | 102 (22) | 105 (23) |
| Postinduction treatment† | ||
| Cycle III | 106 (34) | 96 (31) |
| Auto SCT | 77 (25) | 54 (18) |
| Allo SCT | 128 (41) | 155 (51) |
| Characteristics . | −G-CSF, no. (%) . | +G-CSF, no. (%) . |
|---|---|---|
| Total | 461 (100) | 456 (100) |
| Sex male | 239 (52) | 237 (52) |
| Age, y | ||
| ≤ 35 | 83 (18) | 82 (18) |
| 36-50 | 172 (37) | 167 (37) |
| > 50 | 206 (45) | 207 (45) |
| Range | 18-60 | 17-60 |
| Median | 49 | 49 |
| Prior MDS or chemo/RT | ||
| MDS | 18 (4) | 16 (4) |
| Chemo/RT | 27 (6) | 22 (5) |
| WHO performance status | ||
| 0 | 210 (46) | 208 (46) |
| 1 | 216 (47) | 214 (47) |
| 2 | 28 (6) | 27 (6) |
| 3 | 3 (1) | 1 (0) |
| 4 | 1 (0) | 0 (0) |
| Unknown | 2 (0) | 6 (1) |
| Extramedullary disease* | 56 (12) | 81 (18) |
| WBC | ||
| ≤ 20 × 109/L | 282 (61) | 268 (59) |
| 20-100 × 109/L | 126 (27) | 136 (30) |
| > 100 × 109/L | 53 (11) | 52 (11) |
| AML vs RAEB | ||
| AML | 445 (97) | 428 (94) |
| RAEB | 16 (3) | 28 (6) |
| Cytogenetics | ||
| t(8;21) | 20 (4) | 22 (5) |
| inv(16) | 24 (5) | 28 (6) |
| CN-X-Y | 194 (42) | 213 (47) |
| CA Rest | 145 (31) | 109 (24) |
| MK | 58 (13) | 58 (13) |
| Not done | 20 (4) | 26 (6) |
| Treatment | ||
| Induction treatment | ||
| No | 0 (0) | 1 (0) |
| 1 | 56 (12) | 69 (15) |
| 1 + 2 | 405 (88) | 386 (85) |
| Ara-C dose | ||
| Conventional | 359 (78) | 350 (77) |
| Escalated | 102 (22) | 105 (23) |
| Postinduction treatment† | ||
| Cycle III | 106 (34) | 96 (31) |
| Auto SCT | 77 (25) | 54 (18) |
| Allo SCT | 128 (41) | 155 (51) |